Fed. Circ. Won't Revive Generics' Bid To Ax Takeda Patent
The Federal Circuit on Tuesday declined to revive two India-based generic drug manufacturers' effort to invalidate a patent that Takeda Pharmaceutical Co. uses in a number of its Type II diabetes...To view the full article, register now.
Already a subscriber? Click here to view full article